• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stevanato Group extends licensing agreement with Haselmeier for pen injector tech

January 26, 2022 By Sean Whooley

Stevanato Group Alina pen injector
[Image from Stevanato Group]
Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology.

Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorder, arthritis and more.

The company developed its Alina variable-dose and fixed-dose pen injector platform, compatible with established therapeutic regimens and drug therapies related to diabetes care, through the utilization of the Axis-D technology.

Stevanato Group Head of Product Management for Drug Delivery Systems Adam Stops said in a news release that the Alina platform combines ease of use for patients with faster time-to-market access for pharma organizations.

He added that the extension of the licensing agreement enables Stevanato Group to offer the technology to even more patients in more therapeutic areas as the company continues to expand its capabilities in the drug delivery space.

“The expansion of this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market,” Stevanato Group CEO Franco Moro said. “We are constantly working with our customers to satisfy their needs, as we continue to experience an increase in demand for our high-value solutions and a shift up of the product value chain.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: haselmeier, Stevanato Group

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS